Literature DB >> 26584879

2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.

Constantinos G Neochoritis1, Kan Wang, Natalia Estrada-Ortiz, Eberhardt Herdtweck, Katarzyna Kubica, Aleksandra Twarda, Krzysztof M Zak, Tad A Holak, Alexander Dömling.   

Abstract

The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A rapid and efficient methodology was developed to synthesize the 2,30-bis(10H-indole) heterocyclic scaffold 2 as ester, acid and amide derivatives. Their binding affinity with MDM2 was evaluated using both fluorescence polarization (FP) assay and HSQC experiments, indicating good inhibition and a perfect starting point for further optimizations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584879      PMCID: PMC4764400          DOI: 10.1016/j.bmcl.2015.11.019

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.

Authors:  Anna Czarna; Grzegorz M Popowicz; Aleksandra Pecak; Siglinde Wolf; Grzegorz Dubin; Tad A Holak
Journal:  Cell Cycle       Date:  2009-04-16       Impact factor: 4.534

Review 3.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

4.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

5.  The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

Authors:  Pascal Furet; Patrick Chène; Alain De Pover; Thérèse Stachyra Valat; Joanna Hergovich Lisztwan; Joerg Kallen; Keiichi Masuya
Journal:  Bioorg Med Chem Lett       Date:  2012-03-30       Impact factor: 2.823

Review 6.  p53--a natural cancer killer: structural insights and therapeutic concepts.

Authors:  Lin Römer; Christian Klein; Alexander Dehner; Horst Kessler; Johannes Buchner
Journal:  Angew Chem Int Ed Engl       Date:  2006-10-06       Impact factor: 15.336

7.  A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride.

Authors:  T Okauchi; M Itonaga; T Minami; T Owa; K Kitoh; H Yoshino
Journal:  Org Lett       Date:  2000-05-18       Impact factor: 6.005

Review 8.  MDM2--master regulator of the p53 tumor suppressor protein.

Authors:  J Momand; H H Wu; G Dasgupta
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

9.  Cyclic guanidine organic catalysts: what is magic about triazabicyclodecene?

Authors:  Matthew K Kiesewetter; Marc D Scholten; Nicole Kirn; Ryan L Weber; James L Hedrick; Robert M Waymouth
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

10.  Rationalizing tight ligand binding through cooperative interaction networks.

Authors:  Bernd Kuhn; Julian E Fuchs; Michael Reutlinger; Martin Stahl; Neil R Taylor
Journal:  J Chem Inf Model       Date:  2011-12-09       Impact factor: 4.956

View more
  8 in total

1.  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

Authors:  Constantinos G Neochoritis; Jack Atmaj; Aleksandra Twarda-Clapa; Ewa Surmiak; Lukasz Skalniak; Lisa-Maria Köhler; Damian Muszak; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Barbara Beck; Tad A Holak; Alexander Dömling
Journal:  Eur J Med Chem       Date:  2019-08-06       Impact factor: 6.514

2.  A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Authors:  Lukasz Skalniak; Aleksandra Twarda-Clapa; Constantinos G Neochoritis; Ewa Surmiak; Monika Machula; Aneta Wisniewska; Beata Labuzek; Ameena M Ali; Sylwia Krzanik; Grzegorz Dubin; Matthew Groves; Alexander Dömling; Tad A Holak
Journal:  FEBS J       Date:  2019-02-16       Impact factor: 5.542

3.  Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure.

Authors:  Eman M M Abdelraheem; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  J Org Chem       Date:  2016-09-15       Impact factor: 4.354

Review 4.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

5.  Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.

Authors:  Constantinos G Neochoritis; Maryam Kazemi Miraki; Eman M M Abdelraheem; Ewa Surmiak; Tryfon Zarganes-Tzitzikas; Beata Łabuzek; Tad A Holak; Alexander Dömling
Journal:  Beilstein J Org Chem       Date:  2019-02-20       Impact factor: 2.883

Review 6.  Recent Synthetic Approaches towards Small Molecule Reactivators of p53.

Authors:  Jerson L Silva; Carolina G S Lima; Luciana P Rangel; Giulia D S Ferretti; Fernanda P Pauli; Ruan C B Ribeiro; Thais de B da Silva; Fernando C da Silva; Vitor F Ferreira
Journal:  Biomolecules       Date:  2020-04-20

Review 7.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13

8.  Artificial Macrocycles as Potent p53-MDM2 Inhibitors.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Aleksandra Twarda-Clapa; Bogdan Musielak; Tad A Holak; Alexander Dömling
Journal:  ACS Med Chem Lett       Date:  2017-09-20       Impact factor: 4.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.